About

About Huntington Disease

About

About Huntington Disease

Danielle Lehman

July 19, 2019

HNDC Selected to Participate in Phase 3 Trial of Valbenazine

Danielle Lehman

July 19, 2019

Congratulations! Your site has been selected to participate in the Phase 3 trial to assess the efficacy, safety, and tolerability of Valbenazine for the treatment of Chorea associated with Huntington disease. Th.png

Older PostUpdate on RG6042 (formerly known as IONIS-HTTRx) Huntington’s disease global development programme: Two clinical studies to begin by end of 2018

Contact us today to schedule a consultation.

Get in touch →

CHDI Foundation

Huntington Study Group

© Copyright 2016 Hereditary Neurological Disease Centre